Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:1.2.7.5 (AOR)
 1,763 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Background: Treatment outcomes among MDR-TB patients receiving ethambutol, cycloserine or terizidone as part of a standardized regimen were compared, determining occurrence of serious adverse drug events (SADEs).Methods: Newly-diagnosed adult MDR-TB patients were enrolled between 2000 and 2004, receiving a standardised multidrug regimen for 18-24 months, including ethambutol, cycloserine or terizidone. Cycloserine and terizidone were recorded individually. SADEs and factors associated with culture conversion and unfavourable treatment outcomes (default, death, treatment failure) were determined.Results: Of 858 patients, 435 (51%) received ethambutol, 278 (32%) cycloserine and 145 (17%) terizidone. Demographic and baseline clinical data were comparable. Successful treatment occurred in 56%, significantly more in patients receiving cycloserine (60%) and terizidone (62%) compared with ethambutol (52% [p=0.03]). Defaults rates were 30% in ethambutol patients versus 15% and 11% for cycloserine and terizidone patients respectively. Terizidone was associated with fewer unfavourable outcomes (adjusted odds ratio [AOR] 0.4, p=0.008, 95% CI 0.2-0.8). Patients receiving cycloserine were more likely to achieve culture conversion than those receiving ethambutol or terizidone (AOR 2.2, p=0.02, 95% CI 1.12 - 4.38). Failure to convert increased the odds of unfavourable outcomes (AOR 23.7, p<0.001, 95% CI 13-44). SADEs were reported in two patients receiving ethambutol, seven patients receiving cycloserine and three receiving terizidone (p=0.05).Conclusion: Ethambutol was associated with high culture conversion and default rates. Cycloserine achieved higher culture conversion rates than terizidone. Fewer patients on terizidone experienced SADEs, with lower default rates. The differences we observed between cycloserine and terizidone require further elucidation.
 ...
PMID:Treatment outcomes and adverse drug effects of ethambutol, cycloserine and terizidone for treatment of multi-drug resistant tuberculosis in South Africa. 3304 91